Business Description
Eton Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US29772L1089
Total Employee Number:
44Compare
Compare
Traded in other countries / regions
ETON.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2018-11-14Description
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.63 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.02 | |||||
Debt-to-EBITDA | 5.03 | |||||
Interest Coverage | 0.58 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 9.46 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 52.1 | |||||
3-Year FCF Growth Rate | 67.3 | |||||
3-Year Book Growth Rate | 23.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 48.13 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.83 | |||||
9-Day RSI | 36.01 | |||||
14-Day RSI | 45.35 | |||||
3-1 Month Momentum % | 21.16 | |||||
6-1 Month Momentum % | 118.75 | |||||
12-1 Month Momentum % | 118.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 156.24 | |||||
Days Sales Outstanding | 58.02 | |||||
Days Payable | 103.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -1.23 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.77 | |||||
Operating Margin % | 2.35 | |||||
Net Margin % | -1.7 | |||||
EBITDA Margin % | 7.13 | |||||
FCF Margin % | 0.06 | |||||
OCF Margin % | 14.33 | |||||
ROE % | -5.75 | |||||
ROA % | -1.54 | |||||
ROIC % | 4.74 | |||||
3-Year ROIIC % | 21.64 | |||||
ROC (Joel Greenblatt) % | 44.31 | |||||
ROCE % | 3.53 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 154.89 | |||||
Forward PE Ratio | 85.73 | |||||
PE Ratio without NRI | 81.75 | |||||
PS Ratio | 19.03 | |||||
PB Ratio | 52.55 | |||||
Price-to-Free-Cash-Flow | 817.49 | |||||
Price-to-Operating-Cash-Flow | 107 | |||||
EV-to-EBIT | 98.98 | |||||
EV-to-EBITDA | 77.42 | |||||
EV-to-Forward-EBITDA | 39.71 | |||||
EV-to-Revenue | 15.29 | |||||
EV-to-Forward-Revenue | 10.55 | |||||
EV-to-FCF | 24835.58 | |||||
Price-to-GF-Value | 2.95 | |||||
Earnings Yield (Greenblatt) % | 1.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ETON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eton Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 105.595 | ||
| EPS (TTM) ($) | 0.38 | ||
| Beta | -0.4101 | ||
| 3-Year Sharpe Ratio | 1.54 | ||
| 3-Year Sortino Ratio | 4.2 | ||
| Volatility % | 66.5 | ||
| 14-Day RSI | 45.35 | ||
| 14-Day ATR ($) | 2.41108 | ||
| 20-Day SMA ($) | 44.2595 | ||
| 12-1 Month Momentum % | 118.11 | ||
| 52-Week Range ($) | 14.27 - 59.79 | ||
| Shares Outstanding (Mil) | 27.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eton Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eton Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 85 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 84 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | 42.05 (-3.56%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 42.05 (-3.56%) | ||
| General meeting for 2026 | 2026-06-09 10:00 | 29.95 (+1.77%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 09:55 | 27.61 (+1.47%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 30.82 (+4.44%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 30.82 (+4.44%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 16:30 | 19.02 (+1.06%) | ||
| Annual report for 2025 | 2026-03-19 | 19.02 (+1.06%) |
Show
Entries
Eton Pharmaceuticals Inc Frequently Asked Questions
What is Eton Pharmaceuticals Inc(ETON)'s stock price today?
The current price of ETON is $58.86. The 52 week high of ETON is $59.79 and 52 week low is $14.27.
When is next earnings date of Eton Pharmaceuticals Inc(ETON)?
The next earnings date of Eton Pharmaceuticals Inc(ETON) is 2026-11-06 Est..
Does Eton Pharmaceuticals Inc(ETON) pay dividends? If so, how much?
Eton Pharmaceuticals Inc(ETON) does not pay dividend.
Guru Commentaries on NAS:ETON
No articles.
Press Release
Articles on Eton Pharmaceuticals Inc
Headlines
See More- 1
Aug 14, 2026
Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance
Seeking Alpha • 4:13am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers